Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Ngl Fine Chem
Join Channel
Consolidated Standalone

NGL Fine-Chem

₹2040.1 -7.5 | 0.4%

Market Cap ₹1260 Cr.

Stock P/E 30.5

P/B 4.5

Current Price ₹2040.1

Book Value ₹ 453.7

Face Value 5

52W High ₹2822.5

Dividend Yield 0.09%

52W Low ₹ 1728.6

Edit Ratio

NGL Fine-Chem Research see more...

Stocx User

NGL Fine Chem Ltd

Overview Inc. Year: 1981Industry: Pharmaceuticals & Drugs

NGL Fine-Chem Ltd is engaged in pharmaceutical commercial enterprise. The Company is a producer of prescription drugs and intermediates for utilization in veterinary and human health. Its merchandise consist of Active Pharmaceutical Ingredients (APIs) animal health, APIs human health, Intermediates and finished dosage form categories. The APIs animal health products encompass Homidium Chloride, Clorsulon, Parvaquone, Carprofen, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Amitraz, Praziquantel, Flunixin Meglumine, S-Methoprene, Imidocarb Dipropionate and Nitroxynil. The APIs human health merchandise encompass Nitazoxanide, Atovaquone, Febuxostat and Ranolazine. The Intermediates products consist of 4 Aminobenzamidine Dihydrochloride, 3-Aminobenzamidine Dihydrochloride, Aceturic Acid and 3-Trichlorovinyl Aniline Hydrochloride. The Finished dosage form products consist of Diminazene Aceturate Granules and Homidium Chloride Tablets. The Company has production plants positioned in Mumbai.

Read More..

NGL Fine-Chem Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

NGL Fine-Chem Quarterly Results

#(Fig in Cr.) Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 65 68 72 74 71 80 88 100 91 93
Other Income 3 0 1 2 3 3 4 4 6 5
Total Income 68 68 73 76 74 83 92 103 97 99
Total Expenditure 63 59 62 61 61 66 74 84 81 82
Operating Profit 5 10 11 15 13 17 18 20 15 17
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 4 3 1 3 3 3 3 3 3 3
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1 6 9 12 10 14 14 16 12 13
Provision for Tax 0 2 3 3 2 3 4 4 3 4
Profit After Tax 1 5 6 9 9 10 10 12 9 10
Adjustments -0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 1 5 6 9 9 10 10 12 9 10
Adjusted Earnings Per Share 0.8 7.6 10.5 15.1 13.8 17 16.2 19.9 14.9 15.9

NGL Fine-Chem Profit & Loss

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 153 152 258 318 278 339 372
Other Income 4 3 8 11 6 14 19
Total Income 157 155 266 328 284 353 391
Total Expenditure 121 132 178 249 243 285 321
Operating Profit 36 23 88 79 40 68 70
Interest 3 3 2 2 2 2 0
Depreciation 6 8 8 10 11 12 12
Exceptional Income / Expenses 0 0 0 0 0 0 0
Profit Before Tax 28 12 78 67 27 54 55
Provision for Tax 7 4 21 17 7 13 15
Profit After Tax 20 8 57 50 20 41 41
Adjustments 0 -0 -0 -0 -0 -0 0
Profit After Adjustments 20 8 57 50 20 41 41
Adjusted Earnings Per Share 32.6 13.1 91.6 80.7 33 66.6 66.9

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 22% 10% 17% 0%
Operating Profit CAGR 70% -8% 14% 0%
PAT CAGR 105% -10% 15% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 8% -7% 37% 38%
ROE Average 17% 18% 22% 22%
ROCE Average 20% 22% 26% 26%

NGL Fine-Chem Balance Sheet

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 92 99 154 203 223 263
Minority's Interest 0 0 0 0 0 0
Borrowings 8 8 6 3 2 1
Other Non-Current Liabilities 4 3 5 5 4 6
Total Current Liabilities 45 43 42 66 58 87
Total Liabilities 149 154 207 277 287 356
Fixed Assets 61 68 64 89 88 86
Other Non-Current Assets 2 5 19 15 37 57
Total Current Assets 86 81 125 173 163 213
Total Assets 149 154 207 277 287 356

NGL Fine-Chem Cash Flow

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 1 1 0 2 1 8
Cash Flow from Operating Activities 9 20 27 14 35 20
Cash Flow from Investing Activities -10 -20 -25 -14 -27 -27
Cash Flow from Financing Activities 0 -1 -1 -1 -1 -1
Net Cash Inflow / Outflow -1 -0 2 -1 7 -7
Closing Cash & Cash Equivalent 1 0 2 1 8 0

NGL Fine-Chem Ratios

# Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 32.58 13.14 91.58 80.68 33.04 66.63
CEPS(Rs) 42.78 26.62 105.3 97.55 51.45 85.72
DPS(Rs) 1.75 1.75 1.75 1.75 1.75 1.75
Book NAV/Share(Rs) 149.11 160.18 250.01 328.94 360.23 425.11
Core EBITDA Margin(%) 21.08 13.03 31.05 21.48 12.57 15.87
EBIT Margin(%) 19.66 9.69 30.93 21.58 10.5 16.6
Pre Tax Margin(%) 18 7.96 30.08 20.98 9.84 16.07
PAT Margin (%) 13.14 5.5 21.99 15.72 7.37 12.2
Cash Profit Margin (%) 17.25 10.84 25.22 18.98 11.43 15.64
ROA(%) 13.49 5.5 31.42 20.61 7.27 12.86
ROE(%) 21.85 8.72 44.76 27.9 9.63 17.03
ROCE(%) 25.25 11.93 53.53 33.91 11.96 20.38
Receivable days 78.93 71.37 45.1 58.36 85.22 83.78
Inventory Days 44.35 55.95 46.51 53.95 54.47 37.88
Payable days 89.99 98.81 78.66 72.38 75.67 85.07
PER(x) 14.42 19.28 16.74 24.27 36.22 31.37
Price/Book(x) 3.15 1.58 6.13 5.95 3.32 4.92
Dividend Yield(%) 0.37 0.69 0.11 0.09 0.15 0.08
EV/Net Sales(x) 2.05 1.2 3.72 3.9 2.73 3.91
EV/Core EBITDA(x) 8.63 7.96 10.88 15.7 18.74 19.5
Net Sales Growth(%) 0 -0.97 70.07 23.08 -12.42 21.8
EBIT Growth(%) 0 -51.19 442.89 -14.14 -57.38 92.58
PAT Growth(%) 0 -58.59 580.47 -12.03 -58.92 101.58
EPS Growth(%) 0 -59.67 597.04 -11.91 -59.05 101.66
Debt/Equity(x) 0.29 0.29 0.11 0.15 0.15 0.13
Current Ratio(x) 1.91 1.88 2.98 2.64 2.79 2.46
Quick Ratio(x) 1.5 1.23 2.08 1.79 2.33 1.96
Interest Cover(x) 11.82 5.6 36.21 35.81 15.92 31.07
Total Debt/Mcap(x) 0.09 0.18 0.02 0.02 0.04 0.03

NGL Fine-Chem Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 73.81 73.81 73.81 73.53 73.53 73.06 73.06 72.74 72.74 72.74
FII 0.05 0.05 0 0 0 0.02 0.04 0.1 0.03 0.02
DII 0 0 0 0 0.01 0 0 0 0 0
Public 26.14 26.14 26.19 26.47 26.46 26.92 26.9 27.16 27.23 27.25
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Debtor days have increased from 75.67 to 85.07days.
  • Stock is trading at 4.5 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

NGL Fine-Chem News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!